Man Group PLC Tricida, Inc. Transaction History

Man Group PLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$7.31 - $11.85 $147,742 - $239,500	-20,211 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $148,550 - $214,842	20,211 New	20,211 $166,000
Q4 2018 Feb 14, 2019	SELL	$23.57 - $32.33 $194,947 - $267,401	-8,271 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$22.5 - $39.35 $186,097 - $325,463	8,271 New	8,271 $253,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.